Literature DB >> 28705459

Pre-stroke glycemia in patients with diabetes.

Amrinder Singh1, Desiree D Brooks2, Taryn A Abrams2, Mitra D Poorak2, Drew Gunio2, Prianka K Kandhal2, Aleena Lakhanpal2, Sankara N Sethuraman3, Askiel Bruno4.   

Abstract

AIMS: Hyperglycemia in type 2 diabetes mellitus (T2D) remains uncontrolled in approximately 50% of patients in the United States. Uncontrolled T2D is associated with various vascular complications, including stroke. We studied demographic and clinical factors association with pre-stroke glycemia, indicated by glycated hemoglobin (HbA1c), in acute stroke patients with T2D.
METHODS: Using a questionnaire, we collected demographic, socioeconomic, and clinical information from 300 acute ischemic and hemorrhagic stroke patients in one hospital. We analyzed factors associated with HbA1c in patients with history of T2D.
RESULTS: There were 111 patients with history of T2D and HbA1c measured on admission. In multivariable analyses factors associated with higher HbA1c were treatment with insulin (p=0.05), history of hyperlipidemia (p=0.01), and total cholesterol level (p=0.02). Poor adherence to T2D treatment was associated with higher HbA1c levels (p=0.006) only in a subgroup of patients with HbA1c ≥8%.
CONCLUSION: Insulin treatment and hyperlipidemia are associated with higher HbA1c levels in acute stroke patients with T2D. Poor adherence to diabetes treatment is associated with higher HbA1c levels only among patients with HbA1c ≥8%.
Copyright © 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes; Hyperglycemia; Stroke

Mesh:

Substances:

Year:  2017        PMID: 28705459     DOI: 10.1016/j.dsx.2017.07.011

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  1 in total

1.  Longitudinal Average Glucose Levels and Variance and Risk of Stroke: A Chinese Cohort Study.

Authors:  Xuenan Peng; Jinzhuo Ge; Congju Wang; Hongpeng Sun; Qinghua Ma; Yong Xu; Yana Ma
Journal:  Int J Hypertens       Date:  2020-04-21       Impact factor: 2.420

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.